Mind Medicine (MindMed), Inc. (MNMD)
NASDAQ: MNMD · IEX Real-Time Price · USD
0.874
0.076 (9.48%)
At close: May 27, 2022 4:00 PM
0.878
0.004 (0.423%)
After-hours:May 27, 2022 7:59 PM EDT
Company Description
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology.
The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.
It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Mind Medicine (MindMed), Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 41 |
Contact Details
Address: 1055 West Hastings Street Vancouver, BC V6E 2E9 Canada | |
| Phone | 650 208 2454 |
Stock Details
| Ticker Symbol | MNMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0001813814 |
Key Executives
| Name | Position |
|---|---|
| Robert Barrow | Chief Executive Officer and Director |
| Dr. Miriam Halperin Wernli Ph.D. | Executive President and Director |
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer |
| Dr. Scott M. Freeman | Co-Founder and Clinical Advisor |
| Leonard Latchman | Co-founder |
| Carrie F. Liao CPA, CGMA | Vice President, Corporate Controller and Accounting Principal |
| Wong Hu J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Francois P. Lilienthal M.B.A., M.D. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 26, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 26, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 24, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 23, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 23, 2022 | 3 | Initial statement of beneficial ownership of securities |
| May 23, 2022 | 8-K | Current report |
| May 19, 2022 | 4/A | Statement of changes in beneficial ownership of securities |
| May 19, 2022 | 8-K | Current report |
| May 17, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 20, 2022 | EFFECT | Notice of Effectiveness |
| View All SEC Filings | ||